JP2013509394A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013509394A5 JP2013509394A5 JP2012535996A JP2012535996A JP2013509394A5 JP 2013509394 A5 JP2013509394 A5 JP 2013509394A5 JP 2012535996 A JP2012535996 A JP 2012535996A JP 2012535996 A JP2012535996 A JP 2012535996A JP 2013509394 A5 JP2013509394 A5 JP 2013509394A5
- Authority
- JP
- Japan
- Prior art keywords
- cabazitaxel
- patient
- compound
- label
- prostate cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 claims 28
- 229960001573 cabazitaxel Drugs 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 24
- 206010020751 Hypersensitivity Diseases 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical class CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 8
- 210000000440 neutrophil Anatomy 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- 206010060862 Prostate cancer Diseases 0.000 claims 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 6
- 208000004235 neutropenia Diseases 0.000 claims 6
- 208000026935 allergic disease Diseases 0.000 claims 5
- 230000009610 hypersensitivity Effects 0.000 claims 5
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims 5
- 229960004618 prednisone Drugs 0.000 claims 5
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 5
- 238000004820 blood count Methods 0.000 claims 4
- 238000006243 chemical reaction Methods 0.000 claims 4
- 239000005022 packaging material Substances 0.000 claims 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 3
- 229960003668 docetaxel Drugs 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940088597 hormone Drugs 0.000 claims 3
- 239000005556 hormone Substances 0.000 claims 3
- 238000012544 monitoring process Methods 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 206010015150 Erythema Diseases 0.000 claims 2
- 208000010201 Exanthema Diseases 0.000 claims 2
- 208000001953 Hypotension Diseases 0.000 claims 2
- 231100000321 erythema Toxicity 0.000 claims 2
- 201000005884 exanthem Diseases 0.000 claims 2
- 230000036543 hypotension Effects 0.000 claims 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 229940068968 polysorbate 80 Drugs 0.000 claims 2
- 229960005205 prednisolone Drugs 0.000 claims 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 2
- 206010037844 rash Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 208000002633 Febrile Neutropenia Diseases 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229940095453 prednisone 10 mg Drugs 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25616009P | 2009-10-29 | 2009-10-29 | |
| US61/256,160 | 2009-10-29 | ||
| US29390310P | 2010-01-11 | 2010-01-11 | |
| US61/293,903 | 2010-01-11 | ||
| US35588810P | 2010-06-17 | 2010-06-17 | |
| US35583410P | 2010-06-17 | 2010-06-17 | |
| US61/355,834 | 2010-06-17 | ||
| US61/355,888 | 2010-06-17 | ||
| US36992910P | 2010-08-02 | 2010-08-02 | |
| US61/369,929 | 2010-08-02 | ||
| US38393310P | 2010-09-17 | 2010-09-17 | |
| US61/383,933 | 2010-09-17 | ||
| US38996910P | 2010-10-05 | 2010-10-05 | |
| US61/389,969 | 2010-10-05 | ||
| PCT/IB2010/054866 WO2011051894A1 (en) | 2009-10-29 | 2010-10-27 | Novel antitumoral use of cabazitaxel |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014123108A Division JP6182510B2 (ja) | 2009-10-29 | 2014-06-16 | カバジタキセルの新規の抗腫瘍的使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013509394A JP2013509394A (ja) | 2013-03-14 |
| JP2013509394A5 true JP2013509394A5 (https=) | 2013-10-10 |
| JP5566466B2 JP5566466B2 (ja) | 2014-08-06 |
Family
ID=43567614
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012535996A Active JP5566466B2 (ja) | 2009-10-29 | 2010-10-27 | カバジタキセルの新規の抗腫瘍的使用 |
| JP2014123108A Active JP6182510B2 (ja) | 2009-10-29 | 2014-06-16 | カバジタキセルの新規の抗腫瘍的使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014123108A Active JP6182510B2 (ja) | 2009-10-29 | 2014-06-16 | カバジタキセルの新規の抗腫瘍的使用 |
Country Status (31)
| Country | Link |
|---|---|
| US (8) | US8927592B2 (https=) |
| EP (1) | EP2493466B1 (https=) |
| JP (2) | JP5566466B2 (https=) |
| KR (1) | KR101712231B1 (https=) |
| CN (1) | CN102770131A (https=) |
| AR (1) | AR078824A1 (https=) |
| AU (4) | AU2010310986A1 (https=) |
| BR (1) | BR112012011457A2 (https=) |
| CA (1) | CA2779009A1 (https=) |
| CR (1) | CR20120204A (https=) |
| DK (1) | DK2493466T3 (https=) |
| EA (1) | EA024186B1 (https=) |
| EC (1) | ECSP12011836A (https=) |
| ES (1) | ES2862340T3 (https=) |
| GT (1) | GT201200123A (https=) |
| IL (3) | IL219443A0 (https=) |
| MA (1) | MA33767B1 (https=) |
| MX (1) | MX336339B (https=) |
| MY (1) | MY164086A (https=) |
| NI (1) | NI201200071A (https=) |
| PE (1) | PE20121429A1 (https=) |
| PH (1) | PH12012500848A1 (https=) |
| PL (1) | PL2493466T3 (https=) |
| PT (1) | PT2493466T (https=) |
| SG (1) | SG10201810928SA (https=) |
| SV (1) | SV2012004192A (https=) |
| TN (1) | TN2012000188A1 (https=) |
| TW (2) | TWI533866B (https=) |
| UY (1) | UY32987A (https=) |
| WO (1) | WO2011051894A1 (https=) |
| ZA (1) | ZA201203123B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2926551A1 (fr) | 2008-01-17 | 2009-07-24 | Aventis Pharma Sa | Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation |
| US20120065255A1 (en) * | 2009-10-19 | 2012-03-15 | Nagesh Palepu | Cabazitaxel formulations and methods of preparing thereof |
| CN102770131A (zh) | 2009-10-29 | 2012-11-07 | 安万特医药股份有限公司 | 卡巴他赛的新颖抗肿瘤用途 |
| JP2014514306A (ja) * | 2011-04-12 | 2014-06-19 | プラス・ケミカルス・エスアー | 固体形態のカバジタキセル及びその製造方法 |
| CN102503913B (zh) * | 2011-10-20 | 2014-03-26 | 江苏红豆杉生物科技股份有限公司 | 直接用于x射线单晶衍射分析的二甲氧基紫杉烷类化合物单晶晶体的制备方法 |
| JP6025861B2 (ja) * | 2011-12-13 | 2016-11-16 | アベンティス・ファーマ・ソシエテ・アノニム | カバジタキセルの結晶形およびこれを調製するための方法 |
| WO2013111157A1 (en) * | 2012-01-03 | 2013-08-01 | Shilpa Medicare Limited | Process for preparing amorphous cabazitaxel |
| CN104583189A (zh) | 2012-07-31 | 2015-04-29 | 永信药品工业股份有限公司 | 非晶型的卡巴利他索 |
| TW201438714A (zh) * | 2013-03-04 | 2014-10-16 | Aventis Pharma Sa | 卡巴他賽（ｃａｂａｚｉｔａｘｅｌ）及其治療轉移性前列腺癌之用途 |
| EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| PT3258931T (pt) * | 2015-02-17 | 2020-09-23 | Univ Erasmus Med Ct Rotterdam | Utilização do cabazitaxel no tratamento do cancro da próstata |
| EP3093014A1 (en) | 2015-05-13 | 2016-11-16 | Aventis Pharma S.A. | Cabazitaxel and its use for treating cancer |
| EP3509569A1 (en) | 2016-09-07 | 2019-07-17 | Cadila Healthcare Limited | Sterile injectable compositions comprising drug micelles |
| US10195214B2 (en) | 2017-03-01 | 2019-02-05 | Corcept Therapeutics, Inc. | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
| US20210088505A1 (en) * | 2017-04-07 | 2021-03-25 | La Jolla Institute For Allergy And Immunology | Unipotent Neutrophil Progenitor Cells, Methods of Preparation, and Uses Thereof |
| US20250017891A1 (en) * | 2023-07-04 | 2025-01-16 | Twi Pharmaceuticals, Inc. | Pharmaceutical composition comprising cabazitaxel prodrug-cyclodextrin inclusion complex, and applications thereof |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2601675B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US5005588A (en) | 1989-10-13 | 1991-04-09 | David Rubin | Method for increasing tumor sensitivity to chemotherapy |
| US5714512A (en) | 1991-07-08 | 1998-02-03 | Rhone-Poulenc Rorer, S.A. | Compositions containing taxane derivatives |
| US5750561A (en) | 1991-07-08 | 1998-05-12 | Rhone-Poulenc Rorer, S.A. | Compositions containing taxane derivatives |
| US5698582A (en) | 1991-07-08 | 1997-12-16 | Rhone-Poulenc Rorer S.A. | Compositions containing taxane derivatives |
| FR2698543B1 (fr) | 1992-12-02 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouvelles compositions à base de taxoides. |
| FR2698871B1 (fr) | 1992-12-09 | 1995-02-24 | Rhone Poulenc Rorer Sa | Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent. |
| ZA94128B (en) | 1993-02-01 | 1994-08-19 | Univ New York State Res Found | Process for the preparation of taxane derivatives and betalactam intermediates therefor |
| FR2732340B1 (fr) | 1995-03-27 | 1997-04-30 | Rhone Poulenc Rorer Sa | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
| MA23823A1 (fr) | 1995-03-27 | 1996-10-01 | Aventis Pharma Sa | Nouveaux taxoides, leur preparation et les compositions qui les contiennent |
| US5847170A (en) | 1995-03-27 | 1998-12-08 | Rhone-Poulenc Rorer, S.A. | Taxoids, their preparation and pharmaceutical compositions containing them |
| US6372780B2 (en) | 1995-03-27 | 2002-04-16 | Aventis Pharma S.A. | Methods of treating cell lines expressing multidrug resistance P-glycoprotein |
| FR2745814B1 (fr) | 1996-03-06 | 1998-04-03 | Rhone Poulenc Rorer Sa | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2771092B1 (fr) | 1997-11-18 | 1999-12-17 | Rhone Poulenc Rorer Sa | Procede de preparation de derives de la classe des taxoides |
| US6346543B1 (en) | 1998-08-17 | 2002-02-12 | Aventis Pharma S.A. | Use of a taxoid to treat abnormal cell proliferation in the brain |
| WO2000010547A2 (en) | 1998-08-20 | 2000-03-02 | Aventis Pharma S.A. | New use of taxoid derivatives |
| US6403634B1 (en) | 1999-01-13 | 2002-06-11 | Aventis Pharma S.A. | Use of taxoid derivatives |
| US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| SI1493556T1 (sl) | 2003-07-02 | 2006-02-28 | Scheuten Glasgroep Bv | Postopek za pripravo protipozarne zasteklitve |
| EP1498120A1 (en) | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Semi-solid formulations for the oral administration of taxoids |
| FR2859996B1 (fr) * | 2003-09-19 | 2006-02-03 | Aventis Pharma Sa | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
| GB0425854D0 (en) | 2004-11-25 | 2004-12-29 | Astrazeneca Ab | Therapeutic treatment |
| SG156625A1 (en) | 2004-12-08 | 2009-11-26 | Aventis Pharma Inc | Method for measuring resistance or sensitivity to docetaxel |
| EP1700596A1 (en) | 2005-03-09 | 2006-09-13 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Use of microtubule stabilizing compounds for the treatment of lesions of CNS axons |
| AR054215A1 (es) | 2006-01-20 | 2007-06-13 | Eriochem Sa | Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit |
| FR2922107B1 (fr) | 2007-10-10 | 2010-02-26 | Aventis Pharma Sa | Nouvelles compositions a base de taxoides |
| FR2926551A1 (fr) | 2008-01-17 | 2009-07-24 | Aventis Pharma Sa | Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation |
| EP2177630A1 (en) * | 2008-10-02 | 2010-04-21 | Institut Gustave Roussy | Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family |
| US9427418B2 (en) | 2009-02-23 | 2016-08-30 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
| CN103932972A (zh) | 2009-03-30 | 2014-07-23 | 天蓝制药公司 | 聚合物-药剂缀合物、颗粒、组合物和相关使用方法 |
| FR2945211A1 (fr) | 2009-05-06 | 2010-11-12 | Sanofi Aventis | Combinaison antitumorale comprenant la cabazitaxel et la capecitabine |
| US20110160159A1 (en) | 2009-09-15 | 2011-06-30 | John Ryan | Treatment of cancer |
| US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
| CN102770131A (zh) | 2009-10-29 | 2012-11-07 | 安万特医药股份有限公司 | 卡巴他赛的新颖抗肿瘤用途 |
| ES2621613T3 (es) | 2009-11-04 | 2017-07-04 | Emcure Pharmaceuticals Limited | Un proceso mejorado para la preparación de derivados de taxano |
| AU2010321533A1 (en) | 2009-11-23 | 2012-05-31 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
| WO2011124669A1 (en) | 2010-04-08 | 2011-10-13 | Institut Gustave Roussy | Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family |
| WO2011130317A2 (en) | 2010-04-13 | 2011-10-20 | Amplyx Pharmaceuticals Inc. | Therapeutic agents having reduced toxicity |
| AU2011239569B2 (en) | 2010-04-16 | 2014-07-24 | Baylor College Of Medicine | Method for treating solid tumors |
| EP3093014A1 (en) | 2015-05-13 | 2016-11-16 | Aventis Pharma S.A. | Cabazitaxel and its use for treating cancer |
| EP3808345A1 (en) | 2019-10-15 | 2021-04-21 | Sanofi Mature IP | Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent |
-
2010
- 2010-10-27 CN CN2010800600528A patent/CN102770131A/zh active Pending
- 2010-10-27 MY MYPI2012001871A patent/MY164086A/en unknown
- 2010-10-27 CA CA2779009A patent/CA2779009A1/en not_active Abandoned
- 2010-10-27 EA EA201270606A patent/EA024186B1/ru not_active IP Right Cessation
- 2010-10-27 KR KR1020127013564A patent/KR101712231B1/ko active Active
- 2010-10-27 SG SG10201810928SA patent/SG10201810928SA/en unknown
- 2010-10-27 PE PE2012000581A patent/PE20121429A1/es not_active Application Discontinuation
- 2010-10-27 JP JP2012535996A patent/JP5566466B2/ja active Active
- 2010-10-27 AU AU2010310986A patent/AU2010310986A1/en not_active Abandoned
- 2010-10-27 EP EP10782039.1A patent/EP2493466B1/en active Active
- 2010-10-27 PL PL10782039T patent/PL2493466T3/pl unknown
- 2010-10-27 ES ES10782039T patent/ES2862340T3/es active Active
- 2010-10-27 PH PH1/2012/500848A patent/PH12012500848A1/en unknown
- 2010-10-27 DK DK10782039.1T patent/DK2493466T3/da active
- 2010-10-27 WO PCT/IB2010/054866 patent/WO2011051894A1/en not_active Ceased
- 2010-10-27 PT PT107820391T patent/PT2493466T/pt unknown
- 2010-10-27 BR BR112012011457A patent/BR112012011457A2/pt not_active Application Discontinuation
- 2010-10-27 MX MX2012005030A patent/MX336339B/es unknown
- 2010-10-29 AR ARP100103990 patent/AR078824A1/es unknown
- 2010-10-29 UY UY32987A patent/UY32987A/es unknown
- 2010-10-29 TW TW099137327A patent/TWI533866B/zh active
- 2010-10-29 TW TW104143630A patent/TWI654975B/zh active
-
2012
- 2012-04-25 CR CR20120204A patent/CR20120204A/es unknown
- 2012-04-25 TN TNP2012000188A patent/TN2012000188A1/en unknown
- 2012-04-25 IL IL219443A patent/IL219443A0/en unknown
- 2012-04-26 US US13/456,720 patent/US8927592B2/en active Active
- 2012-04-26 GT GT201200123A patent/GT201200123A/es unknown
- 2012-04-27 EC ECSP12011836 patent/ECSP12011836A/es unknown
- 2012-04-27 SV SV2012004192A patent/SV2012004192A/es unknown
- 2012-04-27 NI NI201200071A patent/NI201200071A/es unknown
- 2012-04-30 ZA ZA2012/03123A patent/ZA201203123B/en unknown
- 2012-05-25 MA MA34898A patent/MA33767B1/fr unknown
-
2014
- 2014-06-16 JP JP2014123108A patent/JP6182510B2/ja active Active
- 2014-12-18 US US14/575,578 patent/US20150118182A1/en not_active Abandoned
- 2014-12-18 US US14/575,566 patent/US20150104411A1/en not_active Abandoned
-
2016
- 2016-02-01 AU AU2016200598A patent/AU2016200598A1/en not_active Abandoned
-
2017
- 2017-01-24 IL IL250254A patent/IL250254A0/en unknown
- 2017-06-20 US US15/627,962 patent/US10583110B2/en active Active
- 2017-09-25 AU AU2017232227A patent/AU2017232227B2/en not_active Ceased
-
2019
- 2019-01-18 US US16/251,143 patent/US20190151278A1/en not_active Abandoned
- 2019-05-20 AU AU2019203514A patent/AU2019203514A1/en not_active Abandoned
- 2019-06-23 IL IL267583A patent/IL267583A/en unknown
-
2020
- 2020-01-15 US US16/743,411 patent/US10716777B2/en active Active
- 2020-07-17 US US16/931,802 patent/US20210169843A1/en not_active Abandoned
-
2023
- 2023-07-20 US US18/224,122 patent/US12453712B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013509394A5 (https=) | ||
| US9737540B2 (en) | Combination treatment of cancer | |
| KR101712231B1 (ko) | 카바지탁셀의 신규한 항종양 용도 | |
| US9370535B2 (en) | Method for treatment of advanced solid tumors | |
| EP3383385B1 (en) | Melflufen dosage regimens for cancer | |
| CN117177743A (zh) | 包含依维莫司和安森司群的组合 | |
| KR20230116837A (ko) | 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법 | |
| KR20230116013A (ko) | 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법 | |
| JP2023551009A (ja) | 持続放出パリペリドン注射可能製剤に関連する投与レジメン | |
| US20130203725A1 (en) | Method to treat small cell lung cancer | |
| AU2016295357A1 (en) | Therapeutic combinations of orally administered paclitaxel and a P-gp inhibitor for the treatment of cancer | |
| US20140323543A1 (en) | Treatment of Prostate Cancer with eIF4E Antisense Compounds | |
| EA049114B1 (ru) | Схемы применения инъекционных составов с пролонгированным высвобождением палиперидона | |
| AU2024259627A1 (en) | Methods of treating hepatic-only metastatic uveal melanoma | |
| JP2018104291A (ja) | マグネシウム化合物を有効成分として含有することを特徴とする医薬組成物 | |
| EA050359B1 (ru) | Схемы применения инъекционных составов с пролонгированным высвобождением палиперидона | |
| JP2018104292A (ja) | マグネシウム化合物を有効成分とする医薬組成物 | |
| Danial | New Drugs Approved by the FDA/New Dosage Forms and Indications Approved by the FDA/New Drug/Biologics License Applications Filed by Manufacturer/Significant Labeling Changes or “Dear Health Professional” Letters Related to Safety | |
| HK1260696A1 (en) | Melflufen dosage regimens for cancer | |
| HK1260696B (en) | Melflufen dosage regimens for cancer | |
| JP2013537232A5 (https=) | ||
| NZ625611B2 (en) | Combination treatment of cancer |